Multisite Inventory of Neonatal-Perinatal Interventions (MINI) Minimum Dataset
Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER, HOUSTON · Jan 6, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Multisite Inventory of Neonatal-Perinatal Interventions (MINI) trial is studying the outcomes and medical practices for extremely premature infants born at 22 to 23 weeks of pregnancy. This research aims to create a detailed registry that helps doctors and hospitals understand the care provided to these tiny babies and how they are doing after birth. The trial is currently recruiting participants, which includes all infants born within this gestational age, whether they need special care in the neonatal intensive care unit (NICU) or not.
If your baby is born between 22 weeks and 23 weeks and 6 days, or if they are admitted to the NICU after being born at this age, they may be eligible to participate. Centers can also choose to include data for babies born before 22 weeks if they wish. Families can expect that their baby's health information will be collected and used to improve care for future infants in similar situations. This study is important as it helps gather valuable information that can lead to better outcomes for extremely premature infants.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All local births with gestational ages of 22 weeks 0 days - 23 weeks 6 days, regardless of pregnancy outcome or neonatal intensive care (NICU) admission; AND
- • All outborn NICU admissions with gestational age at birth of 22 weeks 0 days - 23 weeks 6 days
- • Optional: Centers who desire to include data for NICU admissions of infants born \<22 weeks' gestation may also submit these data.
About The University Of Texas Health Science Center, Houston
The University of Texas Health Science Center at Houston (UTHealth) is a leading academic institution dedicated to advancing health through education, research, and clinical practice. As a prominent sponsor of clinical trials, UTHealth leverages its extensive resources and expertise in biomedical research to facilitate innovative studies aimed at improving patient outcomes. The institution is committed to fostering a collaborative environment that promotes scientific discovery and the translation of research findings into effective healthcare solutions, all while adhering to the highest ethical standards and regulatory guidelines. With a multidisciplinary approach, UTHealth plays a critical role in addressing complex health challenges and enhancing the quality of life in diverse communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
San Diego, California, United States
Boston, Massachusetts, United States
Durham, North Carolina, United States
Iowa City, Iowa, United States
Boston, Massachusetts, United States
Cincinnati, Ohio, United States
Atlanta, Georgia, United States
Houston, Texas, United States
Birmingham, Alabama, United States
Houston, Texas, United States
Portland, Oregon, United States
Greenville, North Carolina, United States
Columbus, Ohio, United States
Mobile, Alabama, United States
Uppsala, , Sweden
Birmingham, Alabama, United States
Jacksonville, Florida, United States
Madison, Wisconsin, United States
Cologne, , Germany
Houston, Texas, United States
Shimotsuke, Tochigi, Japan
San Antonio, Texas, United States
San Antonio, Texas, United States
Richmond, Virginia, United States
Uppsala, Uppland, Sweden
San Antonio, Texas, United States
Orlando, Florida, United States
Orange, California, United States
Kawagoe, Saitama, Japan
Shinkawa, Mitaka, Japan
Azumino, Nagano, Japan
Izumi, Osaka, Japan
Tokyo, , Japan
Phoenix, Arizona, United States
Long Beach, California, United States
San Antonio, Texas, United States
Surrey, British Columbia, Canada
La Paz, , Spain
Patients applied
Trial Officials
Matthew A Rysavy, MD, PhD
Principal Investigator
The University of Texas Health Science Center, Houston
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials